---
title: "Cadrenal's James J. Ferguson III to Resign as Chief Medical Officer, Separation Effective July 31, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293071906.md"
description: "Cadrenal Therapeutics announced that James J. Ferguson III will resign as Chief Medical Officer, with his separation effective July 31, 2026. The departure is under a confidential separation agreement. The company is currently searching for a replacement. This information was disclosed in an SEC 8-K filing dated July 17, 2026."
datetime: "2026-07-17T20:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293071906.md)
  - [en](https://longbridge.com/en/news/293071906.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293071906.md)
---

# Cadrenal's James J. Ferguson III to Resign as Chief Medical Officer, Separation Effective July 31, 2026

**Cadrenal Therapeutics' James J. Ferguson III will resign as Chief Medical Officer, effective July 31, 2026, under a confidential separation agreement.**

**Individual**

James J. Ferguson III

**Role**

Chief Medical Officer

**Type of Change**

Resignation/Separation

**Effective Date**

July 31, 2026

**Reason**

Resigned (as stated by Dr. Ferguson to the Board)

**Replacement Info**

The Company is conducting a search for a replacement

**Background Details**

Not disclosed in the filing

**Board/Committee Role Changes**

Not disclosed

Original SEC Filing: Cadrenal Therapeutics, Inc. \[ CVKD \] - 8-K - Jul. 17, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CVKD.US](https://longbridge.com/en/quote/CVKD.US.md)

## Related News & Research

- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [09:10 ETProcode Raises $10M to Bring Its AI-powered Medical Billing Services to Every Surgical Specialty](https://longbridge.com/en/news/294072246.md)
- [ERG announces availability of H1 2026 interim financial report](https://longbridge.com/en/news/294572882.md)
- [OSK: Q2 2026 sales rose 6.7% but margins declined; 2026 EPS guidance was revised lower](https://longbridge.com/en/news/294100394.md)
- [Regeneron announces Q3 2026 distribution of R$ 0.05 per unit](https://longbridge.com/en/news/294532948.md)